Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans

P. C. Konturek, S. J. Konturek, K. Celinski, M. Slomka, H. Cichoz-Lach, W. Bielanski, Russel J Reiter

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Melatonin and its precursor, l-tryptophan, have been shown to exert gastroprotective effects in animals, but their influence on the gastric damage by aspirin (ASA) in humans has been sparingly investigated. In this study, we designed to determine the effects of melatonin and l-tryptophan on ASA-induced gastric mucosal damage, gastric microbleeding, mucosal generation of prostaglandin E2, and plasma melatonin, and gastrin levels. Three groups of healthy male volunteers (n = 30) with intact gastric mucosa received daily for 11 days either ASA alone or that combined with melatonin or tryptophan. Gastric blood loss and mucosal damage were evaluated at 3rd, 7th, and 11th days of ASA administration by endoscopy using Lanza score. ASA alone caused a marked rise of gastric damage and gastric blood loss, mainly at day 3rd and 7th, but they were significantly reduced at 11th day. Pretreatment with melatonin or tryptophan remarkably reduced ASA-induced gastric lesions and microbleeding. Gastric mucosal generation of PGE2 was suppressed by about 90% in all subjects treated with ASA alone without or with addition of melatonin or tryptophan. Plasma melatonin was markedly increased after treatment with melatonin or tryptophan plus ASA, but it was also raised significantly after application of ASA alone. Plasma gastrin levels were raised in subjects given melatonin or tryptophan plus ASA, but not in those with ASA alone. We conclude that melatonin and its precursor tryptophan given orally significantly reduce gastric lesions induced by ASA possibly due to (a) direct gastroprotective action of exogenous melatonin or that generated from tryptophan and (b) gastrin released from the gastric mucosa by melatonin or tryptophan.

Original languageEnglish (US)
Pages (from-to)318-323
Number of pages6
JournalJournal of Pineal Research
Volume48
Issue number4
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Melatonin
Aspirin
Stomach
Tryptophan
Gastrins
Gastric Mucosa
Dinoprostone
Endoscopy
Healthy Volunteers

Keywords

  • Aspirin
  • Gastric damage
  • Gastrin
  • Gastroprotection
  • L-tryptophan
  • Melatonin

ASJC Scopus subject areas

  • Endocrinology

Cite this

Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. / Konturek, P. C.; Konturek, S. J.; Celinski, K.; Slomka, M.; Cichoz-Lach, H.; Bielanski, W.; Reiter, Russel J.

In: Journal of Pineal Research, Vol. 48, No. 4, 05.2010, p. 318-323.

Research output: Contribution to journalArticle

Konturek, PC, Konturek, SJ, Celinski, K, Slomka, M, Cichoz-Lach, H, Bielanski, W & Reiter, RJ 2010, 'Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans', Journal of Pineal Research, vol. 48, no. 4, pp. 318-323. https://doi.org/10.1111/j.1600-079X.2010.00755.x
Konturek, P. C. ; Konturek, S. J. ; Celinski, K. ; Slomka, M. ; Cichoz-Lach, H. ; Bielanski, W. ; Reiter, Russel J. / Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. In: Journal of Pineal Research. 2010 ; Vol. 48, No. 4. pp. 318-323.
@article{f562d39a14bf4a56a1bc2f47126c07ea,
title = "Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans",
abstract = "Melatonin and its precursor, l-tryptophan, have been shown to exert gastroprotective effects in animals, but their influence on the gastric damage by aspirin (ASA) in humans has been sparingly investigated. In this study, we designed to determine the effects of melatonin and l-tryptophan on ASA-induced gastric mucosal damage, gastric microbleeding, mucosal generation of prostaglandin E2, and plasma melatonin, and gastrin levels. Three groups of healthy male volunteers (n = 30) with intact gastric mucosa received daily for 11 days either ASA alone or that combined with melatonin or tryptophan. Gastric blood loss and mucosal damage were evaluated at 3rd, 7th, and 11th days of ASA administration by endoscopy using Lanza score. ASA alone caused a marked rise of gastric damage and gastric blood loss, mainly at day 3rd and 7th, but they were significantly reduced at 11th day. Pretreatment with melatonin or tryptophan remarkably reduced ASA-induced gastric lesions and microbleeding. Gastric mucosal generation of PGE2 was suppressed by about 90{\%} in all subjects treated with ASA alone without or with addition of melatonin or tryptophan. Plasma melatonin was markedly increased after treatment with melatonin or tryptophan plus ASA, but it was also raised significantly after application of ASA alone. Plasma gastrin levels were raised in subjects given melatonin or tryptophan plus ASA, but not in those with ASA alone. We conclude that melatonin and its precursor tryptophan given orally significantly reduce gastric lesions induced by ASA possibly due to (a) direct gastroprotective action of exogenous melatonin or that generated from tryptophan and (b) gastrin released from the gastric mucosa by melatonin or tryptophan.",
keywords = "Aspirin, Gastric damage, Gastrin, Gastroprotection, L-tryptophan, Melatonin",
author = "Konturek, {P. C.} and Konturek, {S. J.} and K. Celinski and M. Slomka and H. Cichoz-Lach and W. Bielanski and Reiter, {Russel J}",
year = "2010",
month = "5",
doi = "10.1111/j.1600-079X.2010.00755.x",
language = "English (US)",
volume = "48",
pages = "318--323",
journal = "Journal of Pineal Research",
issn = "0742-3098",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans

AU - Konturek, P. C.

AU - Konturek, S. J.

AU - Celinski, K.

AU - Slomka, M.

AU - Cichoz-Lach, H.

AU - Bielanski, W.

AU - Reiter, Russel J

PY - 2010/5

Y1 - 2010/5

N2 - Melatonin and its precursor, l-tryptophan, have been shown to exert gastroprotective effects in animals, but their influence on the gastric damage by aspirin (ASA) in humans has been sparingly investigated. In this study, we designed to determine the effects of melatonin and l-tryptophan on ASA-induced gastric mucosal damage, gastric microbleeding, mucosal generation of prostaglandin E2, and plasma melatonin, and gastrin levels. Three groups of healthy male volunteers (n = 30) with intact gastric mucosa received daily for 11 days either ASA alone or that combined with melatonin or tryptophan. Gastric blood loss and mucosal damage were evaluated at 3rd, 7th, and 11th days of ASA administration by endoscopy using Lanza score. ASA alone caused a marked rise of gastric damage and gastric blood loss, mainly at day 3rd and 7th, but they were significantly reduced at 11th day. Pretreatment with melatonin or tryptophan remarkably reduced ASA-induced gastric lesions and microbleeding. Gastric mucosal generation of PGE2 was suppressed by about 90% in all subjects treated with ASA alone without or with addition of melatonin or tryptophan. Plasma melatonin was markedly increased after treatment with melatonin or tryptophan plus ASA, but it was also raised significantly after application of ASA alone. Plasma gastrin levels were raised in subjects given melatonin or tryptophan plus ASA, but not in those with ASA alone. We conclude that melatonin and its precursor tryptophan given orally significantly reduce gastric lesions induced by ASA possibly due to (a) direct gastroprotective action of exogenous melatonin or that generated from tryptophan and (b) gastrin released from the gastric mucosa by melatonin or tryptophan.

AB - Melatonin and its precursor, l-tryptophan, have been shown to exert gastroprotective effects in animals, but their influence on the gastric damage by aspirin (ASA) in humans has been sparingly investigated. In this study, we designed to determine the effects of melatonin and l-tryptophan on ASA-induced gastric mucosal damage, gastric microbleeding, mucosal generation of prostaglandin E2, and plasma melatonin, and gastrin levels. Three groups of healthy male volunteers (n = 30) with intact gastric mucosa received daily for 11 days either ASA alone or that combined with melatonin or tryptophan. Gastric blood loss and mucosal damage were evaluated at 3rd, 7th, and 11th days of ASA administration by endoscopy using Lanza score. ASA alone caused a marked rise of gastric damage and gastric blood loss, mainly at day 3rd and 7th, but they were significantly reduced at 11th day. Pretreatment with melatonin or tryptophan remarkably reduced ASA-induced gastric lesions and microbleeding. Gastric mucosal generation of PGE2 was suppressed by about 90% in all subjects treated with ASA alone without or with addition of melatonin or tryptophan. Plasma melatonin was markedly increased after treatment with melatonin or tryptophan plus ASA, but it was also raised significantly after application of ASA alone. Plasma gastrin levels were raised in subjects given melatonin or tryptophan plus ASA, but not in those with ASA alone. We conclude that melatonin and its precursor tryptophan given orally significantly reduce gastric lesions induced by ASA possibly due to (a) direct gastroprotective action of exogenous melatonin or that generated from tryptophan and (b) gastrin released from the gastric mucosa by melatonin or tryptophan.

KW - Aspirin

KW - Gastric damage

KW - Gastrin

KW - Gastroprotection

KW - L-tryptophan

KW - Melatonin

UR - http://www.scopus.com/inward/record.url?scp=77950630864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950630864&partnerID=8YFLogxK

U2 - 10.1111/j.1600-079X.2010.00755.x

DO - 10.1111/j.1600-079X.2010.00755.x

M3 - Article

VL - 48

SP - 318

EP - 323

JO - Journal of Pineal Research

JF - Journal of Pineal Research

SN - 0742-3098

IS - 4

ER -